Product Description
Mycophenolic acid is a member of the class of 2-benzofurans that is 2-benzofuran-1(3H)-one which is substituted at positions 4, 5, 6, and 7 by methyl, methoxy, (2E)-5-carboxy-3-methylpent-2-en-1-yl, and hydroxy groups, respectively. It has a role as an antineoplastic agent, an antimicrobial agent, an EC 1.1.1.205 (IMP dehydrogenase) inhibitor, an immunosuppressive agent, a mycotoxin, a Penicillium metabolite, an environmental contaminant, a xenobiotic and an anticoronaviral agent (Sourced from: https://pubchem.ncbi.nlm.nih.gov/compound/Mycophenolic-acid)
Mechanisms of Action: IMPDH Inhibitor,Calcineurin Inhibitor,Immunosuppressive
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: None *
Approval Status: Approved
Approved Countries: Algeria | Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | China | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Morocco | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: BASEL V8 CH 4056
Company CEO: Vasant Narasimhan
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Australia, Belgium, China, Czech Republic, France, Germany, India, Italy, Japan, Netherlands, New Zealand, Norway, Spain, United Kingdom, United States
Active Clinical Trial Count:
Highest Development Phases
Phase 3: Kidney Diseases|Kidney Transplant|Lung Transplant|Lupus Nephritis|Multiple Sclerosis|Renal Transplant
Phase 2: Acute Lymphoid Leukemia|Acute Myeloid Leukemia|Biphenotypic Acute Leukemia|Cardiomyopathy, Dilated|Chronic Lymphoid Leukemia|Chronic Myeloid Leukemia|Geographic Atrophy|Heart Failure|Lupus Erythematosus, Systemic|Lymphocytic Chronic B-Cell Leukemia|Lymphoma, B-Cell|Lymphoma, Non-Hodgkin|Macular Degeneration|Myelodysplastic Syndrome|Myelogenous, Chronic, BCR-ABL Positive Leukemia|Oncology Solid Tumor Unspecified|Precursor B-Cell Lymphoblastic Leukemia-Lymphoma|Precursor Cell Lymphoblastic Leukemia-Lymphoma|Precursor T-Cell Lymphoblastic Leukemia-Lymphoma|Purpura, Thrombocytopenic, Idiopathic|Retinal Degeneration|Retinitis Pigmentosa|T-Cell Cutaneous Lymphoma|T-Cell Leukemia|Thrombocytopenia
Phase 1: Acute Monocytic Leukemia|Acute Myelomonocytic Leukemia|Chronic Myelomonocytic Leukemia|Graft vs Host Disease|Hepatitis B|Intestinal Diseases|Juvenile Myelomonocytic Leukemia,|Liver Transplant|Myeloproliferative Disorders|Preleukemia|Stem Cell Transplant|Transplantation Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| IM103-402 | P3 |
Recruiting |
Kidney Transplant|Renal Transplant |
2030-12-30 |
|
| 2023-505788-35-00 | P2 |
Unknown Status |
Purpura, Thrombocytopenic, Idiopathic|Thrombocytopenia |
2028-01-13 |
|
| STREAM | P2 |
Unknown Status |
Retinitis Pigmentosa |
2027-06-02 |
|
| jRCT2033240447 | P2 |
Recruiting |
Cardiomyopathy, Dilated|Heart Failure |
2027-03-31 |